All stock lists
Novo Nordisk A/S (New York Stock Exchange:NVO)
DK · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - General
40.19-0.26 (-0.64%)
Market cap
$179B
Insider Score
Health Score
Analyst consensus
Listed since
Apr 30, 1981
Website
Insider Score
––Not scored
NVO Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
NVO analyst forecast
NVO analyst consensus
Hold2 ratings
Buy 0 Hold 1 Sell 1
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
NVO 12-month price target
$40.00-0.5% downsideaverage of 1 firm
$40.00High
$40.00Low
NVO ratings mix, last 12 months
Buy Hold Sell
Best analysts covering NVO
- Morgan Stanley100%success rate · +30.1% avg return · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
NVO analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | BMO Capital | Market Perform | — | — | Reiterated | 2026-10-12 |
| Morgan Stanley | Underweight | $40.00 | -9.1% | Downgraded | 2026-09-11 | |
| — | Goldman Sachs | Neutral | — | — | Downgraded | 2026-03-02 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2026-02-24 |
| — | Argus Research | Hold | — | — | Downgraded | 2025-12-08 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2025-11-28 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2025-11-25 |
| — | HSBC | Hold | — | — | Downgraded | 2025-11-24 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2025-10-14 |
| — | HSBC | Buy | — | — | Upgraded | 2025-10-02 |
| — | Morgan Stanley | Underweight | — | — | Downgraded | 2025-09-29 |
| — | Berenberg | Buy | — | — | Upgraded | 2025-09-17 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-08-19 |
| — | UBS | Neutral | — | — | Downgraded | 2025-08-05 |
| — | HSBC | Hold | — | — | Downgraded | 2025-07-31 |
| — | Barclays | Equal Weight | — | — | Downgraded | 2025-07-30 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-06-18 |
| — | BMO Capital | Market Perform | — | — | Downgraded | 2025-04-17 |
| — | UBS | Buy | — | — | Upgraded | 2025-01-08 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-12-23 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-11-06 |
| — | Citigroup | Buy | — | — | Reiterated | 2024-10-22 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-10-17 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-10-16 |
| — | BMO Capital | Market Perform | — | — | Reiterated | 2024-10-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-10-10 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-16 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-09-09 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-19 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-08-08 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-08-05 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-07-01 |
| — | BMO Capital | Outperform | — | — | Reiterated | 2024-06-25 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-06-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-06-17 |
| — | Argus Research | Buy | — | — | Reiterated | 2024-06-10 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-04-18 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-04-05 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-04-01 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-03-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-03-08 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-02-20 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-02-15 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-02-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2024-02-01 |
| — | Argus Research | Buy | — | — | Reiterated | 2024-02-01 |
| — | TD Cowen | Outperform | — | — | Reiterated | 2023-12-04 |
| — | Argus Research | Buy | — | — | Reiterated | 2023-12-01 |
| — | TD Cowen | Outperform | — | — | Reiterated | 2023-03-29 |
| — | BTIG | Buy | — | — | Reiterated | 2023-03-28 |
| — | TD Cowen | Outperform | — | — | Reiterated | 2022-12-12 |
| — | UBS | Sell | — | — | Downgraded | 2022-06-28 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2022-06-07 |
| — | Guggenheim | Buy | — | — | Upgraded | 2022-05-31 |
| — | Deutsche Bank | Buy | — | — | Upgraded | 2022-03-16 |
| — | Liberum | Sell | — | — | Downgraded | 2022-01-25 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2021-12-20 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2021-01-15 |
| — | JMP Securities | Outperform | — | — | Reiterated | 2020-09-02 |
NVO earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-03 | 0.90 | 1.00 | $12.13B | $12.50B |
| 2026-05-06 | 0.87 | 1.04 | $10.86B | $11.02B |
| 2026-08-05 | 0.82 | 0.96 | $10.89B | $12.13B |
| 2026-11-04 | 0.73 | 0.00 | $11.07B | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.